As Alembic books sales of Abilify with a one quarter lag, the impact of price erosion and loss of market share have not reflected in the 3QFY16 numbers. We estimate ~US$ 45mn Abilify revenues in 3Q. Staff costs are up 48% YoY and the new base is likely to be recurring. The company is also investing aggressively in R&D; (up 130% YoY).